LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Solana Beach, CA, US. The stock last traded at $3.92, up 5.24% on the session, giving a market capitalisation of $122.8M. On trailing twelve-month figures it carries a trailing P/E of -0.96, a net margin of -586.7%. Its beta of 1.63 implies it has historically moved more than the broad market.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
LENZ Therapeutics, Inc. is most often compared with the following Healthcare names: